MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.
Martin ReckErnest NadalNicolas GirardAndrea R FilippiLinda W MartinCarl M GayCordula PetersenDavina GaleUgochinyere A EmeribeNefeli GeorgouliaIgnacio E Diaz PerezJonathan D SpicerPublished in: Clinical lung cancer (2024)
Enrollment began in February 2024; primary completion is anticipated in April 2026.